search
Back to results

Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exercise Program (ATOPE)

Primary Purpose

Breast Neoplasms

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
ATOPE-B
ATOPE-I
Sponsored by
Universidad de Granada
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Neoplasms focused on measuring Breast neoplasm, Breast cancer, therapeutic exercise, cardiotoxicity, muscle toxicity

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years or older
  • Breast cancer diagnosis I-III stage
  • On the waiting list to anticancer medical treatment (at least surgery, chemotherapy and radiotherapy.
  • If they meet other criteria which predisposes to higher toxicity.
  • Have signed informed consent.
  • Have medical clearance for participation.

Exclusion Criteria:

  • Patient underwent previous cancer treatments.
  • Patients were previously diagnosed with cancer.
  • Pregnant patients.
  • Patients performing other type of therapeutic exercise at diagnosis time with an intake >or = to 150 moderate-intensity or 75 min of vigorous-intensity a day.
  • Therapeutic exercise practice not recommended because psychiatric or cognitive disorders or cute or chronic condition that prevents exercise (advanced lung disease, oxygen requirement, stenosis >70%, metastasis etc.).

Sites / Locations

  • University of GranadaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

ATOPE-B

ATOPE-I

Arm Description

An adapted therapeutic exercise program performed before medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).

An adapted therapeutic exercise program performed during medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).

Outcomes

Primary Outcome Measures

Left ventricular ejection fraction
To assess cardiac toxicity by echocardiography

Secondary Outcome Measures

Cardiovascular events
Number of cardiovascular events registered in a diary
Resting heart rate
To assess cardiac function by a Holter
Heart Rate variability
To assess cardiac autonomic system balance by a Holter
Muscle loss
To assess muscle mass loss by Inbody
Quality of life with the Quality of Life Questionnaire (QLQ)-C30
With the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) version 3.0. It is used to asses quality of life. It contains 30 items with both multi-item scales and single-item measures. Values are assigned between 1 and 4 (1: not at all, 2: a little, 3: enough, 4: a lot) according to the patient's responses to the item, only in items 29 and 30 evaluate with a score of 1 to 7 (1: lousy, 7: excellent). The scores obtained are standardized and a score between 0 and 100 is obtained, which determines the level of cancer impact on the patient of each of the scales. The high values in the scales of global health and function state indicate a better CV, while in the scale of symptoms it would indicate a decrease in CV since it indicates the presence of symptoms associated with cancer.
Quality of life with the Quality of life Questionnaire (QLQ- BR23) a specific module.
European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23). It is a breast cancer module of EORTC QLQ-C30. This module contains 23 items assessing symptoms and side effects related to different treatment modalities, body image, sexuality, and future perspective. After the scoring procedures for the QLQ-C30, all scale and single-item scores are linearly transformed to a 0 to 100 scale. For the functional scales and single items (ie, body image, sexuality, and future perspective), higher scores represent a better level of functioning. For the symptom scales and single item, a higher score represents a higher level of symptoms.
Chemotherapy regimen
type of chemotherapy agent used and number of sessions.
Chemotherapy doses modifications
delay of doses or reduction, total doses received from the total expected.
Early session termination.
Patient stopped receiving chemotherapy before last >=1 sessions.
Missing bouts due to adverse effects of chemotherapy
Adverse effects of chemotherapy treatment and if it was interrupted (>=3 missing consecutive bouts of exercise)
Number of hospitalizations.
Therapeutic exercise bout modification
>=1 bout that required a dose modification during the program and number of bouts modified in total.
Time to treatment failure
days from the start to the end of chemotherapy, if it was terminated for toxicity and/or tumor progression.
Program adverse effects reported by the participants.
Frequency of serious and non-serious events occurring during program.
Functional capacity
assessed by the 6-Minute Walking Test
Handgrip strength
assessed by a digital dynamometer: TKK 5101 Grip-D; Takey, Tokyo, Japan
Shoulder strength
assessed by an isokinetic test with an isokinetic dynamometer (HUMAC NORM)
Lower limb strength
assessed by an isokinetic test with an isokinetic dynamometer (HUMAC NORM)
Abdominal strength
assessed by an isokinetic test with an isokinetic dynamometer (HUMAC NORM)
Flexibility
assessed by the Modified sit-and-reach test
Waist and hip circumferences
assessed by an inelastic tape
Body composition
assessed by the InBody
Oxidative stress
Thiobarbituric acid reactive substances (TBARS)
Oxidative stress
carbonyls and 8-hydroxy-2' -deoxyguanosine (8-OHdG)
Inmune function
Number of lymphocytes: (cluster of differentiation (CD) 8 and 4 and regulatory T lymphocytes)
inflammation
C-reactive protein (CRP)
inflammation
interleukin (IL) 6 and 10
inflammation
tumor necrosis factor (TNF) alpha
inflammation
insulin-like growth factor 1 (IGF-1)

Full Information

First Posted
December 14, 2018
Last Updated
May 30, 2023
Sponsor
Universidad de Granada
search

1. Study Identification

Unique Protocol Identification Number
NCT03787966
Brief Title
Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exercise Program
Acronym
ATOPE
Official Title
Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exercise Program: Study Protocol of the ATOPE Trial in Women Recently Diagnosed With Breast Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2019 (Actual)
Primary Completion Date
December 30, 2024 (Anticipated)
Study Completion Date
January 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidad de Granada

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The aim of this study is to determine if therapeutic exercise before anticancer treatment will mitigate the onset or extent of cardiotoxicity comparing to therapeutic exercise performed during anticancer treatment.
Detailed Description
The positive relationship between physical exercise and cancer is widely justified in the literature, but an emerging research line warns of its capacity to improve the effectiveness and reduce the toxicity of cancer treatment (responsible for the appearance of side effects and comorbidities), that overload the health care system. To date, there is a lack of knowledge in different subjects: the possibility of implementing individualized exercise programs in clinical environment to mitigate the side effects of cancer treatment; the best moment in natural history of the disease to perform therapeutic exercise; and a tailored dose of exercise that maximizes its benefits. In this context, the present study will evaluate the effects of a therapeutic exercise program conducted previously at the beginning of the cancer treatment, in the treatments' toxicity against the same program conducted during cancer treatments in women with breast cancer, and its positive effects on both clinical and biological variables and their possible impact on disease-free survival. This study will be conducted in 3 phases with 110 participants in total: phase 1: a pilot study be carried out to check the feasibility of the proposed physical exercise program; phase 2: to test the effectiveness of the program ATOPE performed prior to surgical medical treatment against the same made during treatment, with a randomized controlled clinical trial; and phase 3: in which it will be integrated into the health service and a larger project will be requested at the international level.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Neoplasms
Keywords
Breast neoplasm, Breast cancer, therapeutic exercise, cardiotoxicity, muscle toxicity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
110 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ATOPE-B
Arm Type
Experimental
Arm Description
An adapted therapeutic exercise program performed before medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).
Arm Title
ATOPE-I
Arm Type
Active Comparator
Arm Description
An adapted therapeutic exercise program performed during medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).
Intervention Type
Other
Intervention Name(s)
ATOPE-B
Other Intervention Name(s)
Therapeutic exercise before medical treatment
Intervention Description
Patients will perform therapeutic exercise before medical treatment and will follow the usual care after medical treatment.
Intervention Type
Other
Intervention Name(s)
ATOPE-I
Other Intervention Name(s)
Therapeutic exercise during medical treatment
Intervention Description
Patients will follow usual care before medical treatment and will perform therapeutic exercise after medical treatment.
Primary Outcome Measure Information:
Title
Left ventricular ejection fraction
Description
To assess cardiac toxicity by echocardiography
Time Frame
Participants will be followed over 12 months
Secondary Outcome Measure Information:
Title
Cardiovascular events
Description
Number of cardiovascular events registered in a diary
Time Frame
Participants will be followed over 12 months
Title
Resting heart rate
Description
To assess cardiac function by a Holter
Time Frame
Participants will be followed over 12 months
Title
Heart Rate variability
Description
To assess cardiac autonomic system balance by a Holter
Time Frame
Participants will be followed over 12 months
Title
Muscle loss
Description
To assess muscle mass loss by Inbody
Time Frame
Participants will be followed over 12 months
Title
Quality of life with the Quality of Life Questionnaire (QLQ)-C30
Description
With the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) version 3.0. It is used to asses quality of life. It contains 30 items with both multi-item scales and single-item measures. Values are assigned between 1 and 4 (1: not at all, 2: a little, 3: enough, 4: a lot) according to the patient's responses to the item, only in items 29 and 30 evaluate with a score of 1 to 7 (1: lousy, 7: excellent). The scores obtained are standardized and a score between 0 and 100 is obtained, which determines the level of cancer impact on the patient of each of the scales. The high values in the scales of global health and function state indicate a better CV, while in the scale of symptoms it would indicate a decrease in CV since it indicates the presence of symptoms associated with cancer.
Time Frame
Participants will be followed over 12 months
Title
Quality of life with the Quality of life Questionnaire (QLQ- BR23) a specific module.
Description
European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23). It is a breast cancer module of EORTC QLQ-C30. This module contains 23 items assessing symptoms and side effects related to different treatment modalities, body image, sexuality, and future perspective. After the scoring procedures for the QLQ-C30, all scale and single-item scores are linearly transformed to a 0 to 100 scale. For the functional scales and single items (ie, body image, sexuality, and future perspective), higher scores represent a better level of functioning. For the symptom scales and single item, a higher score represents a higher level of symptoms.
Time Frame
Participants will be followed over 12 months but will not be assessed in baseline
Title
Chemotherapy regimen
Description
type of chemotherapy agent used and number of sessions.
Time Frame
Participants will be followed over 12 months
Title
Chemotherapy doses modifications
Description
delay of doses or reduction, total doses received from the total expected.
Time Frame
Participants will be followed over 12 months
Title
Early session termination.
Description
Patient stopped receiving chemotherapy before last >=1 sessions.
Time Frame
Participants will be followed over 12 months
Title
Missing bouts due to adverse effects of chemotherapy
Description
Adverse effects of chemotherapy treatment and if it was interrupted (>=3 missing consecutive bouts of exercise)
Time Frame
Participants will be followed over 12 months
Title
Number of hospitalizations.
Time Frame
Participants will be followed over 12 months
Title
Therapeutic exercise bout modification
Description
>=1 bout that required a dose modification during the program and number of bouts modified in total.
Time Frame
Participants will be followed over 12 months
Title
Time to treatment failure
Description
days from the start to the end of chemotherapy, if it was terminated for toxicity and/or tumor progression.
Time Frame
Participants will be followed over 12 months
Title
Program adverse effects reported by the participants.
Description
Frequency of serious and non-serious events occurring during program.
Time Frame
Participants will be followed over 12 months
Title
Functional capacity
Description
assessed by the 6-Minute Walking Test
Time Frame
Participants will be followed over 12 months
Title
Handgrip strength
Description
assessed by a digital dynamometer: TKK 5101 Grip-D; Takey, Tokyo, Japan
Time Frame
Participants will be followed over 12 months
Title
Shoulder strength
Description
assessed by an isokinetic test with an isokinetic dynamometer (HUMAC NORM)
Time Frame
Participants will be followed over 12 months
Title
Lower limb strength
Description
assessed by an isokinetic test with an isokinetic dynamometer (HUMAC NORM)
Time Frame
Participants will be followed over 12 months
Title
Abdominal strength
Description
assessed by an isokinetic test with an isokinetic dynamometer (HUMAC NORM)
Time Frame
Participants will be followed over 12 months
Title
Flexibility
Description
assessed by the Modified sit-and-reach test
Time Frame
Participants will be followed over 12 months
Title
Waist and hip circumferences
Description
assessed by an inelastic tape
Time Frame
Participants will be followed over 12 months
Title
Body composition
Description
assessed by the InBody
Time Frame
Participants will be followed over 12 months
Title
Oxidative stress
Description
Thiobarbituric acid reactive substances (TBARS)
Time Frame
Participants will be followed over 12 months
Title
Oxidative stress
Description
carbonyls and 8-hydroxy-2' -deoxyguanosine (8-OHdG)
Time Frame
Participants will be followed over 12 months
Title
Inmune function
Description
Number of lymphocytes: (cluster of differentiation (CD) 8 and 4 and regulatory T lymphocytes)
Time Frame
Participants will be followed over 12 months
Title
inflammation
Description
C-reactive protein (CRP)
Time Frame
Participants will be followed over 12 months
Title
inflammation
Description
interleukin (IL) 6 and 10
Time Frame
Participants will be followed over 12 months
Title
inflammation
Description
tumor necrosis factor (TNF) alpha
Time Frame
Participants will be followed over 12 months
Title
inflammation
Description
insulin-like growth factor 1 (IGF-1)
Time Frame
Participants will be followed over 12 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years or older Breast cancer diagnosis I-III stage On the waiting list to anticancer medical treatment (at least surgery, chemotherapy and radiotherapy. If they meet other criteria which predisposes to higher toxicity. Have signed informed consent. Have medical clearance for participation. Exclusion Criteria: Patient underwent previous cancer treatments. Patients were previously diagnosed with cancer. Pregnant patients. Patients performing other type of therapeutic exercise at diagnosis time with an intake >or = to 150 moderate-intensity or 75 min of vigorous-intensity a day. Therapeutic exercise practice not recommended because psychiatric or cognitive disorders or cute or chronic condition that prevents exercise (advanced lung disease, oxygen requirement, stenosis >70%, metastasis etc.).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Irene Cantarero-Villanueva, PhD
Phone
958248764
Email
irenecantarero@ugr.es
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Irene Cantarero-Villanueva, PhD
Organizational Affiliation
Physical Therapy Deparment, Faculty of Health Sciences, University of Granada
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Granada
City
Granada
ZIP/Postal Code
18016
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Irene Cantarero-Villanueva, PhD
Phone
958248764
First Name & Middle Initial & Last Name & Degree
Manuel Arroyo-Morales, PhD

12. IPD Sharing Statement

Citations:
PubMed Identifier
36076044
Citation
Postigo-Martin P, Gil-Gutierrez R, Moreno-Gutierrez S, Lopez-Garzon M, Gonzalez-Santos A, Arroyo-Morales M, Cantarero-Villanueva I. mHealth system (ATOPE+) to support exercise prescription in breast cancer survivors: a reliability and validity, cross-sectional observational study (ATOPE study). Sci Rep. 2022 Sep 8;12(1):15217. doi: 10.1038/s41598-022-18706-7.
Results Reference
derived
PubMed Identifier
33528004
Citation
Postigo-Martin P, Penafiel-Burkhardt R, Gallart-Aragon T, Alcaide-Lucena M, Artacho-Cordon F, Galiano-Castillo N, Fernandez-Lao C, Martin-Martin L, Lozano-Lozano M, Ruiz-Vozmediano J, Moreno-Gutierrez S, Illescas-Montes R, Arroyo-Morales M, Cantarero-Villanueva I. Attenuating Treatment-Related Cardiotoxicity in Women Recently Diagnosed With Breast Cancer via a Tailored Therapeutic Exercise Program: Protocol of the ATOPE Trial. Phys Ther. 2021 Mar 3;101(3):pzab014. doi: 10.1093/ptj/pzab014.
Results Reference
derived

Learn more about this trial

Attenuating Cancer Treatment-related Toxicity in Oncology Patients With a Tailored Physical Exercise Program

We'll reach out to this number within 24 hrs